dc.contributor.author
Garcia Vidal, Carolina
dc.contributor.author
Cardozo Espinola, Celia
dc.contributor.author
Puerta-Alcalde, Pedro
dc.contributor.author
Marco Reverté, Francesc
dc.contributor.author
Tellez, Adrian
dc.contributor.author
Agüero, Daiana
dc.contributor.author
Romero Santana, Francisco
dc.contributor.author
Díaz Beyà, Marina
dc.contributor.author
Giné Soca, Eva
dc.contributor.author
Morata, Laura
dc.contributor.author
Rodríguez Núñez, Olga
dc.contributor.author
Martínez, José Antonio
dc.contributor.author
Mensa Pueyo, Josep
dc.contributor.author
Esteve, Jordi
dc.contributor.author
Soriano Viladomiu, Alex
dc.date.issued
2019-02-20T15:29:20Z
dc.date.issued
2019-02-20T15:29:20Z
dc.date.issued
2018-06-28
dc.date.issued
2019-02-14T15:59:51Z
dc.identifier
https://hdl.handle.net/2445/128531
dc.description.abstract
Objectives: We assess the epidemiology and risk factors for mortality of bloodstream infection (BSI) in patients with acute leukemia (AL). Methods:
Prospectively collected data of a cohort study from July 2004 to February 2016. Multivariate analyses were performed. Results: 589 episodes of BSI were documented in 357 AL patients, 55% caused by gram-positive bacteria (coagulase-negative staphylococci 35.7%, Enterococcus spp 10.8%) and 43.5% by gram-negative bacteria (E. coli 21%, PA 12%). We identified 110 (18.7%) multidrug-resistant (MDR) microorganisms, especially MDR-Pseudomonas aeruginosa (7%) and extended-spectrum beta-lactamase producing Enterobacteriaceae (7%). The 30-day mortality was 14.8%. Age (OR 3.1; 95% CI 1.7–5.7); chronic lung disease (4.8; 1.1–21.8); fatal prognosis according to McCabe index (13.9; 6.4–30.3); shock (3.8; 1.9–7.7); pulmonary infection (3.6; 1.3–9.9); and MDR-PA infections with inappropriate treatment (12.8; 4.1–40.5) were related to mortality. MDR-PA BSI was associated to prior antipseudomonal cephalosporin use (9.31; 4.38–19.79); current use of betalactams (2.01; 1.01–4.3); shock (2.63; 1.03–6.7) and pulmonary source of infection (9.6; 3.4–27.21). Conclusions: MDR organisms were commonly isolated in BSI in AL. Inappropriate empiric antibiotic treatment for MDR-PA is the primary factor related to mortality that can be changed. New treatment strategies to improve the coverage of MDR-PA BSI should be considered in those patients with risk factors for this infection.
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Public Library of Science (PLoS)
dc.relation
Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0199531
dc.relation
PLoS One, 2018, vol. 13, num. 6, p. e0199531
dc.relation
http://dx.doi.org/ 10.1371/journal.pone.0199531
dc.rights
cc by (c) Garcia Vidal, 2018
dc.rights
http://creativecommons.org/licenses/by/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (ISGlobal)
dc.title
Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion